Blog
RSS FeedPosted by Michael Wonder on 07 Feb 2022
Medicines Australia calls for new National Medicines Policy to be pushed back until after the federal election
4 February 2022 - Medicines Australia is today calling for the new National Medicines Policy to be pushed back until ...
Posted by Michael Wonder on 02 Feb 2022
ABPI analysis on NICE’s changes for evaluating new medicines: next steps
31 January 2022 - NICE has published a new Manual, which sets out how the latest medicines and health technologies ...
Posted by Michael Wonder on 02 Feb 2022
Review of the National Medicines Policy – consultation on the draft closes 16 February 2022
2 February 2022 - Since August 2021, the Committee has heard from nearly 200 stakeholders through bilateral interviews and virtual group ...
Posted by Michael Wonder on 31 Jan 2022
NICE publishes new combined methods and processes manual and topic selection manual for its health technology evaluation programmes
31 January 2022 - Changes to the way medicines and other health technologies are evaluated by NICE have now been incorporated ...
Posted by Michael Wonder on 30 Jan 2022
How are child specific utility instruments used in decision making in Australia? A review of Pharmaceutical Benefits Advisory Committee public summary documents.
28 January 2022 - Measuring and valuing health-related quality of life in children can be challenging but is an important component ...
Posted by Michael Wonder on 21 Jan 2022
National Medicines Policy Review – publication of submissions
21 January 2022 - On 30 August 2021, the National Medicines Policy Review Committee invited submissions to support the Review of ...
Posted by Michael Wonder on 20 Jan 2022
NICE moves: increased accessibility and flexibility for health tech
19 January 2022 - NICE also aims to make strides in digital, genomic and antimicrobial technologies ...
Posted by Michael Wonder on 19 Jan 2022
UK’s NICE to launch sweeping changes to drug assessments to be faster, more agile
19 January 2022 - The health technology assessment body has been under pressure from drugmakers and patient groups for years to ...
Posted by Michael Wonder on 19 Jan 2022
Early benefit assessment for new drugs 2021: G-BA sets a record with 146 completed procedures
10 January 2022 - At the beginning of the year, the Federal Joint Committee (G-BA) took stock of its assessment of ...
Posted by Michael Wonder on 18 Jan 2022
TGA in review (2021)
19 January 2022 - Using a liberal definition of what constitutes a 'new medicine', we have determined the TGA approved ...
Posted by Michael Wonder on 11 Jan 2022
FDA approved more first in class drugs, gave more accelerated approvals in 2021
7 January 2022 - The US Food and Drug Administration’s Center for Drug Evaluation and Research approved 50 new drug therapies ...
Posted by Michael Wonder on 20 Dec 2021
PHARMAC’s year in review
20 December 2021 - Today PHARMAC has released its Year in Review for 2021, an annual publication highlighting key aspects of ...
Posted by Michael Wonder on 11 Dec 2021
‘All I want for Christmas’ is higher prices: Congressional report accuses pharma of manipulating Americans for profit
10 December 2021 - It was the day before Christmas in 2015 and a senior director of national accounts at ...
Posted by Michael Wonder on 07 Dec 2021
Shining a light on PHARMAC
6 December 2021 - It is encouraging to read the country’s drug buying agency PHARMAC is already moving to improve ...
Posted by Michael Wonder on 04 Dec 2021
Reforms needed for FDA’s regulation of medical devices
3 December 2021 - Medical devices are mainstays of modern medicine, from basic products like gloves and bandages to complex ...